Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.44 |
| ▸ | PAICS | P22234 | 12/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21571673 | 0.82 | ALDH1A1 (0.36) | SMYD3PAICSALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL20339062 | 0.82 | PAICS (0.45) | SMYD3PAICS | |
| SCHEMBL20339051 | 0.78 | PAICS (0.55) | PAICS | |
| SCHEMBL21571651 | 0.77 | PAICS (0.38) | PAICSALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21571660 | 0.77 | PAICS (0.45) | SMYD3PAICS | |
| SCHEMBL24220469 | 0.76 | SMYD3 (0.41) | SMYD3PAICS | |
| SCHEMBL21571672 | 0.76 | PAICS (0.52) | SMYD3PAICSCHEK1 | |
| SCHEMBL20352176 | 0.75 | SMYD3 (0.41) | SMYD3PAICS | |
| SCHEMBL20340330 | 0.72 | PAICS (0.45) | SMYD3PAICSCYP1A2CYP2C19 | |
| SCHEMBL21571674 | 0.70 | PAICS (0.35) | SMYD3PAICS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | LIFEARC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | PAICS, CDK12, CDK13 | SMYD3 3357/4885PAICS 1/4885CHEK1 1179/4885 |
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | PAICS, CDK13, CDK12 | SMYD3 3327/4885PAICS 1/4885CHEK1 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.